EMA Wants More Staff For Continuing Pandemic Workload

Agency Expects 11 COVID-19-Related Product Applications This Year

The more products the European Medicines Agency approves, the more post-authorization applications it receives, leading to an ever-growing spiral in its workload. This, together with the increase in COVID-19-related tasks, new responsibilities in clinical trials and other areas, and a decline in staff numbers over the years, is posing some real resource issues at the agency.

Corona Virus symbol on blue yellow european union EU flag europe background. Cornavirus COVID-19 global outbreak pandemic epidemic medical concept.
The EMA is under continuing pressure from COVID-19 • Source: Alamy

The European Medicines Agency has again called for more resources to help it deal with the ongoing impact of COVID-19 as well as the general increase in its workload. It has specifically asked to retain 40 temporary staff posts that were created to help deal with pandemic-related activities during 2021-22 but that are scheduled to disappear in 2023.

Despite the “exceptional circumstances” it has faced over recent years, the EMA says it has managed to adapt to a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

Swissmedic Appoints Trivigno As New Agency Head From 2026

 

Vincenza Trivigno will take over as executive director from Raimund Bruhin, who is retiring after over seven years in the post.

New EFPIA President Hopes ‘Sanity Will Prevail’ In EU Pharma Reform Dialogs

 

Stefan Oelrich, the newly-announced president of European pharma industry federation EFPIA says the EU pharma reform is “not an improvement on the status quo” in its current form.

Denmark Introduces First Confidential Pricing Framework For Primary Care Medicines

 

Expanded confidential pricing for pharmaceuticals is intended to help manage medicines expenditure, according to Amgros, the procurement agency that will negotiate the prices.

Repurposed Drugs: EU Pharma Reform Offers Boost, But Payers ‘Must Recognize Health Gains’

 

Incentives for repurposed drugs proposed as part of the EU pharma reform package are a “great step forward,” but more recognition is needed from payers and regulators to leverage the benefits of these medicines, experts say.

More from Geography

New EFPIA President Hopes ‘Sanity Will Prevail’ In EU Pharma Reform Dialogs

 

Stefan Oelrich, the newly-announced president of European pharma industry federation EFPIA says the EU pharma reform is “not an improvement on the status quo” in its current form.

UK Pilots Faster Setup Of Early Phase Oncology Trials

 
• By 

Oncology trial sponsors in the UK are being invited to participate in a pilot that aims to tackle duplication and variation in pharmacy reviews, which are an important part of setting up clinical trials in the National Health Service.

US CDC Vaccine Committee Revives Thimerosal Debate: A Portent Of Things To Come?

 

The new Advisory Committee on Immunization Practices voted for new recommendations on the decades-old thimerosal safety issue and lays intellectual groundwork to revisit other past controversies and decisions.